Management
Tomas Lindström, born in 1967, boasts a PhD in solid state physics from Uppsala University and a wealth of experience in pioneering technology startups. His career highlights include serving as Head of Development at Åmic AB (acquired by Johnson & Johnson) and as Co-founder/Development Manager at Fiomi Diagnostics AB (acquired by Trinity Biotech). Lindström’s investment in Psilox includes 67 500 shares, representing about 3.47% of the company, along with 114 000 stock options.
Lindström is also actively involved in board commitments with AB Concentrus and Perendinus Technologies AB.